The Patent Cliff Is Here. Is Your Life Sciences Talent Strategy Ready?
April 2026EPM Scientific6 min read
The Patent Cliff Is Here. Is Your Life Sciences Talent Strategy Ready?
Key takeaway
The patent cliff is reshaping the life sciences talent market as much as it is impacting revenue. Cost programs are releasing experienced professionals into the market at the same time that biosimilars, pipeline reinvestment, and outsourcing are increasing demand for the same profiles. This window of increased talent availability is unlikely to last. Organizations that align hiring with how the market is moving now will be in a stronger position than those that react later. Waiting is not a neutral decision. It increases the risk of capability gaps emerging just as regulatory, manufacturing, and commercial pressure intensifies.
What is the patent cliff in life sciences?
The patent cliff refers to the period when a large number of high-revenue drugs lose patent protection, allowing generic and biosimilar competition to enter the market. Between 2025 and 2030, around $300 billion in global prescription drug revenue is expected to lose exclusivity.
This shift affects more than revenue. It changes hiring demand, increases competition for specialist talent, and reduces how long experienced candidates remain available.
This scale of revenue exposure, covering close to one-sixth of the industry’s annual income, is already influencing workforce planning decisions well ahead of formal portfolio transitions. Close to 190 drugs are expected to lose exclusivity over the next five years, and the workforce decisions being made in anticipation of those losses are already reshaping the life sciences talent market.
The conversations we are having with hiring managers and candidates across the sector consistently point to a shift that goes well beyond large pharma organizations managing portfolio transitions.
How the life sciences talent market is shifting in 2026
Candidate availability has increased in the short term, but demand is already building and will reduce that availability quickly.
The candidate market for specialist life sciences talent has shifted more in the past 18 months than it did in the several years before that. Professionals who would rarely have engaged during the growth cycle are now receptive to conversations, and in a number of functions the quality of passive candidates available is meaningfully higher than it was even a year ago.
That shift is structural rather than cyclical. Cost reduction programs designed years ahead of anticipated patent expiries are now taking effect across the sector.
A Fierce Pharma analysis of annual reports found that the 17 largest pharmaceutical companies collectively reduced their workforces by more than 22,000 roles in 2025 alone. Experienced professionals across regulatory, manufacturing, commercial, and clinical functions have entered the market at the same time.
What is less visible, but equally important, is how unevenly that talent remains available once demand begins to return. In recent searches supported globally, regulatory affairs, quality, and clinical operations roles have shown the shortest availability windows once hiring activity accelerates, with experienced candidates entering multiple processes quickly.
How long the current conditions last is the more critical issue. Biosimilar scale-up, M&A integration, and renewed pipeline investment are all driving demand for the same specialist profiles from different directions. Organizations that engage early are accessing stronger and broader candidate pools than those that wait for pressure to fully materialize.
For companies assessing hiring plans over the next 12 to 18 months, this is the point where early market engagement materially affects access, optionality, and hiring outcomes.
Where demand for life sciences talent is growing
Demand is increasing across biosimilars, pipeline investment, and outsourced development, with organizations competing for the same specialist talent.
While the headlines focus on large pharma revenue losses, the resulting talent pressure is already being felt across the wider life sciences ecosystem. Where an organization sits determines how that pressure shows up, not whether it does.
Biosimilar and Generic Manufacturers
When a blockbuster loses exclusivity, the commercial opportunity for biosimilar and generic manufacturers can materialize quickly. Building the capability to capture it takes considerably longer. Regulatory, quality, and market access professionals with the specific experience these programs require are not in abundant supply, and by the time filing timelines are locked, the strongest candidates are rarely still available.
A typical biosimilar development program runs five to eight years from initial comparability studies through to regulatory submission. The hiring requirement for regulatory, quality, and market access professionals does not sit at the end of that timeline. It usually sits in the middle of it, often 18 to 24 months before a filing is ready. By the time a submission date is confirmed and headcount is approved internally, much of the most experienced talent has already re-entered competing processes elsewhere. The organizations that secure the right talent are those that begin engaging the market before the internal urgency is apparent, not once it is.
Pharma and Biotech companies reinvesting in pipeline
Pipeline reinvestment is where a significant portion of new hiring activity is concentrated. Oncology, immunology, and rare disease continue to attract the most attention, with ADCs and cell therapy seeing sustained investment. AI-enabled drug discovery is also reshaping hiring requirements, raising demand for candidates who combine scientific depth with regulatory understanding. That profile is one of the more challenging searches in the current market.
CDMOs and CROs
As pharma organizations manage costs through the transition period, more manufacturing and development activity is shifting toward contract organizations. For CDMOs and CROs, this means absorbing increased demand while the broader talent market is tightening around the specialist profiles they require. GMP-experienced engineers, quality professionals, process development specialists, clinical operations, and project management talent are all in shorter supply than they were two years ago.
MedTech, Diagnostics and Specialty Pharma
The talent pool for specialist life sciences professionals does not segment neatly by organization type. A MedTech company hiring a regulatory affairs director is competing in the same market as a biosimilar manufacturer doing the same. When that market tightens, the impact is felt across the board regardless of what is driving demand. Hiring strategies based on where the market sat two years ago are already under strain.
Which life sciences roles are hardest to hire right now
The shift in demand is not evenly distributed. Some functions are already experiencing more acute pressure than others. Regulatory affairs, GMP manufacturing and quality, market access, and clinical operations are under the most pressure globally, and understanding where this is concentrated is important for workforce planning over the next 12 to 24 months.
Regulatory Affairs
Demand for experienced regulatory professionals was already outpacing supply before the patent cliff accelerated it further. Biosimilar programs require a different skill set from standard NDA or MAA work, and the volume of filings building across multiple therapeutic areas is stretching a talent pool that takes years to develop.
This pressure is global. In the US, regulatory complexity has increased through recent FDA changes. Across Europe, MDR compliance deadlines and evolving EMA requirements are driving further demand. Salaries and contractor rates have risen across all major markets and show no sign of stabilizing.
For a detailed view of how MDR is affecting hiring across Europe, see our guide to EU MDR and its impact on talent demand.
If you are planning regulatory hires linked to filing timelines, engaging the market at least 12 months in advance is necessary to secure the right profiles before they enter competing processes.
Medical Affairs
Medical affairs has evolved from a largely reactive, field-based function into a more strategic one. It now sits closer to clinical development, commercial planning, and regulatory strategy. The profiles required today combine scientific credibility with the ability to operate across complex stakeholder environments and navigate more rigorous evidence expectations. The pool of candidates who genuinely meet this brief is smaller than many organizations anticipate.
Manufacturing and Quality
GMP-experienced engineers and quality professionals are being pulled in multiple directions. Biosimilar scale-up, cell and gene therapy manufacturing, and reshoring programs are all drawing from the same limited pool across the US, Europe, and Asia Pacific. This is often where gaps between demand and supply become visible first, particularly for organizations that deprioritize these functions early in the hiring process.
Market Access
The Inflation Reduction Act in the US and evolving HTA frameworks across Europe have significantly increased the technical demands on market access functions. Payer negotiations, reimbursement strategy, and health economics work now require deeper and more specialized experience. IQVIA's analysis of revenue exposure through 2030 makes clear that up to 64% of some large pharma companies' current sales are at risk from loss of exclusivity. The commercial stakes of getting market access capability right are unusually high.
Clinical Operations
R&D programs are continuing despite broader restructuring across the sector, and demand for clinical operations professionals reflects that. CRAs, clinical project managers, and site management professionals are stretched globally, and rising trial complexity has raised the experience threshold required for these roles. Organizations that maintain development timelines tend to prioritize this hiring earlier rather than reacting once programs are underway.
What the patent cliff means for workforce planning
Effective workforce planning depends on aligning hiring with pipeline timelines and engaging talent before demand peaks.
The organizations that come out of this period in the strongest position will not necessarily be those with the largest hiring budgets. In our experience, they are typically those that align hiring decisions with pipeline and regulatory timelines, rather than reacting to vacancies once delivery risk has already begun to accumulate.
Deloitte's biopharma trends analysis notes that as roles evolve to leverage advanced tools and automation, organizations should proactively address potential workforce disruptions and consider building capability ahead of need rather than reacting to vacancies.
That means connecting workforce planning to pipeline and product timelines rather than waiting for vacancies to open. It means assessing internal capability before going to market and identifying adjacent skill sets that can be developed. It means maintaining visibility of the candidate market between hires, rather than engaging only when a role becomes urgent. And it means using contract and interim solutions with purpose, particularly for time-bound demands such as regulatory filings and M&A integration.
This is less about moving faster, and more about positioning effectively in a market where timing and access determine outcomes.
The talent window is open, but timing matters
The talent being released into the market through cost programs is real, but it will not remain available for long. Demand is already building across biosimilars, pipeline reinvestment, and outsourced development, all competing for the same specialist profiles.
That leaves a short window where access to experienced talent is higher than it is likely to be in the coming years. For many organizations, the challenge is not identifying the need for talent but aligning hiring strategy with how that talent is actually moving.
Across the searches we support at EPM Scientific, this pattern is already visible. Organizations building capability ahead of pipeline and exclusivity timelines are securing talent that others only approach once it becomes critical.
By contrast, organizations that delay engagement are forced into shorter lists, higher compensation pressure, or interim solutions implemented too late to fully de-risk delivery.
This is where hiring outcomes diverge. Organizations that engage early access a broader, higher-quality talent pool, while those that wait compete for candidates who are already in process elsewhere.
Plan your next hire with EPM Scientific
If you are planning hires in the next 12 to 24 months or reassessing how your workforce strategy aligns with pipeline and product timelines, we can provide a data-backed view of where talent is available now and how that is likely to change.
EPM Scientific is a specialist life sciences recruitment partner operating across the US, Europe, and Asia Pacific. With more than 6,000 life sciences professionals placed, 1,500+ clients supported across 30 countries, and 1,500 specialist consultants globally, we provide market insight that goes beyond active candidates.
Request a call back to understand which specialist roles are likely to become constrained first, how long the current talent window is likely to last, and what that means for your hiring and delivery timelines.
Sources
1. Evaluate — Portfolio Tactics to Scale the $300bn Patent Cliff (2025)
2. Deloitte — Trends Shaping Biopharma (2025)
3. Fierce Pharma — Large pharma companies reduced headcounts by more than 22,000 in 2025 as $300B patent cliff looms (2025)
4. IQVIA — Biopharma M&A: Outlook for 2025
Frequently Asked Questions
The patent cliff is reshaping recruitment in two opposing ways at the same time. Cost reduction programs at large pharma have released experienced professionals into the market across regulatory, clinical, manufacturing, and commercial functions. In the short term, this has improved access to senior-level talent that was largely unavailable during the growth cycle.
At the same time, biosimilar manufacturers, CDMOs, CROs, and pipeline-stage pharma and biotech companies are increasing hiring for those same profiles. As demand returns, experienced candidates are moving quickly between processes. This means availability improves briefly, then tightens rapidly, particularly in specialist functions tied to regulatory filings, manufacturing readiness, and clinical delivery.
Regulatory affairs professionals with direct biosimilar or MDR experience remain among the most constrained globally, reflecting both filing volume and regulatory complexity. GMP-experienced engineers and quality professionals are similarly in short supply, with demand coming simultaneously from biosimilar scale-up, cell and gene therapy manufacturing, and reshoring initiatives.
Market access specialists with deep HTA, health economics, and payer negotiation capability are also difficult to secure, particularly as the Inflation Reduction Act in the US and evolving European reimbursement frameworks increase the technical demands of these roles. Clinical operations roles, including experienced CRAs and clinical project managers, continue to see sustained pressure due to rising trial complexity and ongoing R&D investment.
Waiting carries meaningful risk. The current level of candidate availability reflects workforce reductions implemented well ahead of patent expiries, rather than a structural increase in long-term supply. As biosimilar programs, pipeline reinvestment, and outsourcing continue to accelerate, many of the strongest candidates are already entering multiple hiring processes.
Organizations that engage early are securing broader and higher-quality shortlists, with more flexibility on structure, location, and compensation. Those that wait until a role becomes urgent are more likely to face constrained options, rising cost pressure, or delays that affect regulatory and development timelines.
Layoffs and demand growth are occurring in different parts of the ecosystem at the same time. Large pharma companies are reducing headcount in response to upcoming revenue losses, while biosimilar and generic manufacturers need to build regulatory, quality, and market access capability quickly to capture post-exclusivity opportunity.
At the same time, CDMOs and CROs are absorbing outsourced manufacturing and development work as sponsors manage costs, and biotech and mid-sized pharma companies continue to invest in oncology, rare disease, cell therapy, and AI-enabled drug development. All of these organizations are competing for the same specialist talent, which is why hiring pressure is increasing despite headline reductions in workforce size.
For the most constrained functions, particularly regulatory affairs, GMP manufacturing, quality, and market access, many experienced candidates are no longer available at the moment a vacancy opens. The organizations with the most consistent access to specialist talent tend to maintain ongoing visibility of the candidate market rather than engaging only when headcount approval is in place.
For roles linked to regulatory submissions, product launches, or critical development milestones, planning 12 to 18 months ahead is increasingly necessary. This allows organizations to engage talent before competition peaks, assess adjacent skill sets that can be developed internally, and use interim solutions strategically rather than reactively.